He spent a career reading the sugar coats on proteins, the chemistry most people skip. They turned out to be where the medicine hides.
Inside GlycoEra's pipeline sits a molecule called GE8820. Its job is narrow and unforgiving: find pathogenic IgG4 autoantibodies, the rogue proteins behind certain autoimmune diseases, and degrade them with a speed, depth and selectivity that current drugs cannot reach. The trick is leaving everything else alone. No broad immunosuppression. No collateral damage. Just the offending protein, gone.
That is the bet Ganesh Kaundinya is running as President and CEO. GlycoEra is a glycoengineering company - it works in the language of glycans, the sugar chains that decorate proteins and quietly govern how the body recognizes, sorts and disposes of them. Most of biotech aims its degraders inside the cell. GlycoEra aims outside it, at the extracellular proteins floating in blood and tissue. It is harder. It is also emptier territory, which is exactly the point.
In May 2025 the company closed an oversubscribed $130 million Series B, led by Novo Holdings, with Catalio, LifeArc Ventures and Qatar's QIA joining existing backers Sofinnova Partners, 5AM Ventures, Roche Ventures and Bristol Myers Squibb. The money buys a run at the clinic: push the lead IgG4 degrader through patient data, bring a second program forward, widen the pipeline in immunology.
Kaundinya did not arrive at GlycoEra as a hired hand. He sat on its board from the 2020 inception, helped set the strategy, helped raise the first $49 million. Then in 2022 he took the wheel. The move made sense to anyone who knew his history, because he had built a company out of sugar chemistry once before - and that one sold for $6.5 billion.
The roots run back to MIT. Kaundinya earned his M.S. and Ph.D. in chemical engineering there, then stayed on the research faculty. He ran bioinformatics for the Consortium for Functional Glycomics, a multi-million-dollar NIH effort to decode the role of complex sugars in biology, and worked alongside Robert Langer's lab on technology to sequence those sugars - chains so structurally messy that conventional tools simply gave up on them.
Out of that work came Momenta Pharmaceuticals. Kaundinya co-founded it and grew it from a technology concept into a public company with three FDA-approved products spanning complex generics, biosimilars and novel biologics. The signature win was M-Enoxaparin, a generic of Sanofi-Aventis' blockbuster heparin Lovenox and the first interchangeable generic low molecular weight heparin approved in the United States. Reverse-engineering a drug that complex, well enough for the FDA to call it interchangeable, was a feat of analytical chemistry as much as pharmacology. He served as Chief Scientific Officer, then added Chief Operating Officer in 2017. Johnson & Johnson bought the company in 2020.
So GlycoEra is a second act with the same grammar. Different proteins, different disease, same conviction: that the sugar layer everyone treated as noise is actually the signal. He has been here before, patient with a hard idea while the rest of the field caught up.
"I have been very impressed with the GlycoEra team's accomplishments and am delighted to join them to build the next stage."
Glycans are the sugar chains coating proteins - structurally messy enough that conventional sequencing tools quit. Kaundinya spent two decades treating them as readable signal, not noise.
Most degrader companies work inside the cell. GlycoEra goes after extracellular proteins floating in blood and tissue - harder ground, and far less crowded.
He sat on GlycoEra's board from day one in 2020, shaped its strategy, helped raise its first $49M, then stepped in as CEO in 2022. Conviction, not a parachute.
His science traces to Robert Langer's MIT lab, where cloning and sequencing the heparinase enzyme seeded the technology that became Momenta.
M-Enoxaparin matched Sanofi's Lovenox closely enough for the FDA to call it interchangeable - a feat of analytical chemistry, not just pharmacology.
GlycoEra is registered in Waedenswil near Zurich, tied to the Boston biotech world where he works. A trans-Atlantic build by design.
GlycoEra's pitch for its lead degrader is not just that it removes a disease-driving protein. It is how cleanly it does so. The contrast it draws against broad immunosuppression is the design philosophy in one picture.
Illustrative of GlycoEra's stated design goals for its IgG4-targeted degrader GE8820. Not clinical data.
Momenta grew out of cloning and sequencing the heparinase enzyme in Robert Langer's lab - the kind of footnote that becomes a billion-dollar company.
His backers span Novo Holdings, Sofinnova, 5AM Ventures, Roche Ventures, Bristol Myers Squibb, Catalio, LifeArc Ventures and Qatar's QIA.
GlycoEra lives in Waedenswil, on the lake south of Zurich, and in the Boston biotech orbit at once - a company stitched across an ocean.
He picked the chemistry other people found too hard to sequence, then waited - twice - for the rest of the field to agree it mattered.